Is It Smart To Buy Amoy Diagnostics Co., Ltd. (SZSE:300685) Before It Goes Ex-Dividend?
Is It Smart To Buy Amoy Diagnostics Co., Ltd. (SZSE:300685) Before It Goes Ex-Dividend?
Amoy Diagnostics Co., Ltd. (SZSE:300685) stock is about to trade ex-dividend in 2 days. The ex-dividend date is usually set to be one business day before the record date which is the cut-off date on which you must be present on the company's books as a shareholder in order to receive the dividend. The ex-dividend date is an important date to be aware of as any purchase of the stock made on or after this date might mean a late settlement that doesn't show on the record date. Thus, you can purchase Amoy Diagnostics' shares before the 30th of May in order to receive the dividend, which the company will pay on the 30th of May.
艾德生物股票将于2天后除息。除息日通常设置为股权登记日前一天,即您必须作为股东出现在公司账簿上,才能在分红日收到分红。除息日是需要注意的重要日期,因为在此日期之后或之前购买股票的结算可能会迟到,导致不能在股权登记日显示。因此,您可以在5月30日之前购买艾德生物的股票,以获取30日支付的分红。
The company's next dividend payment will be CN¥0.15 per share. Last year, in total, the company distributed CN¥0.15 to shareholders. Last year's total dividend payments show that Amoy Diagnostics has a trailing yield of 0.8% on the current share price of CN¥18.43. If you buy this business for its dividend, you should have an idea of whether Amoy Diagnostics's dividend is reliable and sustainable. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing.
该公司的下一个分红将为每股人民币0.15元。去年,该公司向股东派发了人民币0.15元的总分红。去年的总分红额表明,艾德生物股票目前的收益率为0.8%。如果您购买该股票是为了分红,您应该了解艾德生物的分红是否可靠和可持续。这就是为什么我们应该始终检查分红支付是否可持续,以及公司的增长情况。
If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. Amoy Diagnostics paid out just 22% of its profit last year, which we think is conservatively low and leaves plenty of margin for unexpected circumstances. A useful secondary check can be to evaluate whether Amoy Diagnostics generated enough free cash flow to afford its dividend. Luckily it paid out just 20% of its free cash flow last year.
如果公司支付的股息大于其盈利,则可能导致股息无法维持,这很不理想。去年,艾德生物仅支付了22%的利润,我们认为这是保守的水平,留有足够的余地用于意外情况。有用的辅助检查是评估艾德生物是否产生足够的自由现金流来支付其股息。幸运的是,去年它只支付了其自由现金流的20%。
It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.
看到股息既有盈利也有现金流的覆盖是令人鼓舞的。这通常表明股息是可持续的,只要收益没有急剧下降。
Click here to see the company's payout ratio, plus analyst estimates of its future dividends.
点击此处查看公司的支付比率以及未来分红的分析师预期。
![historic-dividend](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240528/0-413b39c29586d037df47b51231ebabd0-0-18b72e115e4164dd972a2f139fea73b2.png/big)
Have Earnings And Dividends Been Growing?
收益和股息一直在增长吗?
Stocks in companies that generate sustainable earnings growth often make the best dividend prospects, as it is easier to lift the dividend when earnings are rising. If earnings decline and the company is forced to cut its dividend, investors could watch the value of their investment go up in smoke. For this reason, we're glad to see Amoy Diagnostics's earnings per share have risen 16% per annum over the last five years. The company has managed to grow earnings at a rapid rate, while reinvesting most of the profits within the business. Fast-growing businesses that are reinvesting heavily are enticing from a dividend perspective, especially since they can often increase the payout ratio later.
以产生可持续的盈利增长的公司的股票通常是最好的分红前景,因为在盈利增长时,提高分红比率更容易。如果收益下降并且公司被迫削减股息,则投资者可能会看到其投资价值荡然无存。因此,我们很高兴地看到艾德生物每股收益在过去五年中年平均增长了16%。该公司成功地以快速的速度增长了收益,并将大部分利润重新投资于业务中。从股息的角度来看,这些积极的增长业务尤其具有吸引力,特别是因为它们通常可以在以后增加支付比率。
Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. Since the start of our data, six years ago, Amoy Diagnostics has lifted its dividend by approximately 20% a year on average. Both per-share earnings and dividends have both been growing rapidly in recent times, which is great to see.
衡量公司分红前景的另一个关键方法是衡量其历史分红增长率。自我们的数据开始以来,即六年前,艾德生物每年平均提高约20%的股息。近段时间,每股收益和股息都在快速增长,这是非常好的迹象。
To Sum It Up
总结一下
Is Amoy Diagnostics worth buying for its dividend? Amoy Diagnostics has been growing earnings at a rapid rate, and has a conservatively low payout ratio, implying that it is reinvesting heavily in its business; a sterling combination. It's a promising combination that should mark this company worthy of closer attention.
对于它的分红,艾德生物值得购买吗?艾德生物的每股收益以快速的速度增长,并且分红比率保守且较低,这意味着它正在积极地将资金投入其业务中;这是一个卓越的组合。这是一个值得更加关注的有前途的公司。
In light of that, while Amoy Diagnostics has an appealing dividend, it's worth knowing the risks involved with this stock. For example - Amoy Diagnostics has 1 warning sign we think you should be aware of.
因此,尽管艾德生物具有吸引力的股息,但了解该股票的风险也很重要。例如,请注意-艾德生物有1个警告标志,我们认为您应该了解。
If you're in the market for strong dividend payers, we recommend checking our selection of top dividend stocks.
如果你在寻找强劲的股息支付者,我们建议查看我们的顶级股息股票选择。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或电邮 editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。